Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CFO Howard Horn sold 1,785 shares of the business's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.40, for a total value of $72,114.00. Following the sale, the chief financial officer now owns 106,169 shares in the company, valued at approximately $4,289,227.60. The trade was a 1.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Ultragenyx Pharmaceutical Stock Down 2.9 %
Ultragenyx Pharmaceutical stock opened at $37.50 on Tuesday. The business has a 50-day simple moving average of $42.48 and a 200 day simple moving average of $48.50. Ultragenyx Pharmaceutical Inc. has a 52 week low of $37.02 and a 52 week high of $60.37. The stock has a market cap of $3.47 billion, a price-to-earnings ratio of -5.91 and a beta of 0.67.
Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The firm had revenue of $164.88 million during the quarter, compared to analysts' expectations of $163.23 million. On average, research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.
Wall Street Analysts Forecast Growth
RARE has been the topic of a number of analyst reports. Wells Fargo & Company boosted their price objective on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a research note on Friday, December 20th. Piper Sandler boosted their price objective on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an "overweight" rating in a research note on Monday, January 13th. HC Wainwright reiterated a "buy" rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. JPMorgan Chase & Co. decreased their price objective on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating on the stock in a research note on Thursday, November 21st. Finally, Wedbush reiterated a "neutral" rating and set a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $93.50.
Check Out Our Latest Research Report on Ultragenyx Pharmaceutical
Hedge Funds Weigh In On Ultragenyx Pharmaceutical
A number of hedge funds and other institutional investors have recently modified their holdings of RARE. Principal Financial Group Inc. boosted its holdings in shares of Ultragenyx Pharmaceutical by 740.0% in the 3rd quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company's stock worth $4,802,000 after purchasing an additional 76,150 shares in the last quarter. Atria Investments Inc purchased a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth about $269,000. Victory Capital Management Inc. boosted its holdings in shares of Ultragenyx Pharmaceutical by 8.8% in the 3rd quarter. Victory Capital Management Inc. now owns 10,948 shares of the biopharmaceutical company's stock worth $608,000 after purchasing an additional 884 shares in the last quarter. KBC Group NV boosted its holdings in shares of Ultragenyx Pharmaceutical by 24.5% in the 3rd quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company's stock worth $143,000 after purchasing an additional 506 shares in the last quarter. Finally, Natixis Advisors LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 290.0% in the 3rd quarter. Natixis Advisors LLC now owns 52,562 shares of the biopharmaceutical company's stock worth $2,920,000 after purchasing an additional 39,086 shares in the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.
Ultragenyx Pharmaceutical Company Profile
(
Get Free Report)
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
